QuiVad

Home / United States / AGF U.S. Market Neutral Anti-B (BTAL)

AGF U.S. Market Neutral Anti-B (BTAL)

Short position disclosed on August 31, 2026.

Follow

FINRA publishes, twice a month, the number of shares sold short in each company. Their share of the stock is computed here on the count the company reports to the SEC, and this market appears in no ranking shared with the others.

Evolution of the disclosed total

0250K500K750K1M
Jul 29Aug 12Aug 26Sep 9
Number of shares sold short. Hover or tap the curve to see which funds make it up.

Open positions

The funds disclosing a short position that is still open.
FundTwelve monthsShares sold shortOver the yearSince
Aggregated total873,918 shares+587,596 sharesAugust 31, 2026

Follow by RSS

Get the moves on AGF U.S. Market Neutral Anti-B (BTAL) by mail.

No account: one address, one link to confirm, one link to stop in every message.

History of disclosures

4 disclosures on record for this share.
DateFundShares sold shortEnd of publication
August 31, 2026Aggregated total873,918 sharesstill open
August 14, 2026Aggregated total458,107 shares
July 31, 2026Aggregated total968,046 shares
July 15, 2026Aggregated total286,322 shares

Download 4 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats

Other companies sold short in the United States

Cite this page

The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.

QuiVad, AGF U.S. Market Neutral Anti-B (BTAL), source FINRA, data as at August 31, 2026, https://www.quivad.com/action/agf-u-s-market-neutral-anti-b-btal